All articles by Staff Writer
Staff Writer
Negative pressure, positive outcomes
A new report from the European Wound Management Association (EWMA) outlines the major advancements in negative pressure wound therapy in recent years and addresses the challenges to their implementation in clinical settings. The report’s coauthor, Luc Téot of Montpellier University Hospital, talks Elly Earls through the new guidance and explains why education and telemedicine are crucial to the future of the discipline.
Tackling the TB threat
Dr Martin Obermeier, lab manager at the Medical Centre for Infectious Diseases in Berlin (MIB), shares his expert perspective on the importance of TB testing, and how the T-SPOT.TB test from Revvity is helping his team to combat TB in immunosuppressed patients.
Keeping tuberculosis at bay
Roughly 25% of the world’s population is estimated to be infected with Mycobacterium tuberculosis, with 5–10% risking progression into TB disease. Early diagnosis and detection of drug resistance are, therefore, essential to preventing its impact across the globe – even as related work on new TB vaccines continues apace. Andrea Valentino talks to Kogieleum Naidoo of the Centre for the AIDS Programme of Research in South Africa, to learn more.
Combatting anti-fungal drug resistance
With fungal infections identified as a major public health threat, reliable and accurate antifungal susceptibility testing (AFST) is critical, to ensure effective patient treatment and to combat the rise of drug-resistant strains. Bruker’s antifungal testing assays help to combat these strains.
Taking a breath test
Respiratory virus testing has evolved rapidly in the wake of the Covid-19 pandemic. During that time, health systems around the world had to figure out how to deliver tests on an unprecedented scale and as quickly as possible. This led to the development of new testing options that are available today. Monica Karpinski speaks to three experts in virology to find out how the pandemic has shaped the field and how healthcare professionals can navigate these new advances.
QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Respiratory Panel Mini test for clinical use. It is the third test to receive FDA clearance for use with QIAstat-Dx systems in 2024.
QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Meningitis/Encephalitis Panel for clinical use.
Precision for Medicine and Navinci Announce Strategic Partnership
Precision for Medicine, a leading global precision medicine clinical research organization, is pleased to announce a strategic partnership with Navinci. This collaboration will integrate Navinci’s advanced in situ proximity ligation assay kits into Precision for Medicine’s comprehensive service offerings, empowering researchers with innovative tools to drive deeper insights into protein functions and interactions.
Global TB Summit 2024: QIAGEN leads the charge as tuberculosis reemerges as a leading infectious killer
Thousands of healthcare professionals, advocates, and public policymakers from over 170 countries are set to participate from October 8-11 in the annual Global TB Summit, sponsored by QIAGEN, as the world confronts the resurgence of tuberculosis as one of the deadliest infectious diseases.
Bruker Acquires Dynamic Biosensors, a Pioneer of Single-Cell Interaction Cytometry Systems for Drug Discovery
Combining Dynamic Biosensors’ Innovative Technologies with Bruker’s High-Performance SPR Portfolio to Establish a Leading Biosensors Business